Hospira is voluntarily recalling three lots of the injectable opioid medication Hydromorphone HCl because the glass vials may be broken or cracked, the Food and Drug Administration announced yesterday. Hospira has notified hospitals and others with an existing inventory of the lots subject to this recall that they should stop use and distribution of the remaining units and quarantine them immediately. See the FDA announcement for more information, including the lot numbers. Health care professionals are encouraged to report any related problems or events to the FDA's MedWatch Program. Last week, the AHA and others asked the Drug Enforcement Administration to temporarily adjust the aggregate production quotas for certain injectable opioid medications in short supply to allow other manufacturers to supply product until the shortages resolve.
 

Related News Articles

Headline
Hartford HealthCare in Hartford, Conn., will receive the 2025 AHA Quest for Quality Prize as a result of their sweeping transformation over the past decade —…
Headline
A Q&A in the July edition of AHA Trustee Insights features leaders from Winchester Hospital in Massachusetts discussing the importance of board members…
Headline
To help hospitals across the country improve sepsis care, the Centers for Disease Control and Prevention created the Hospital Sepsis Program Core Elements,…
Headline
AHA President and CEO Rick Pollack explains how hospitals have made meaningful progress in patient safety and delivering high-quality care, in a column…
Headline
The Administration for Strategic Preparedness and Response June 25 announced it conducted an exercise transporting simulated patients with high-consequence…
Headline
Ochsner Health's Stephen Saenz, sepsis program manager, and Teresa Arrington, director of robust process improvement for quality and patient safety, reveal how…